Directory
Manuel Portero Otin

Manuel Portero Otin

Degree: PhD

973 702 408
manuel.portero(ELIMINAR)@udl.cat

ResearcherID: http://www.researcherid.com/rid/B-7122-2009

Groups

Publications

  • Purroy, F; Jove, M; Portero, M; Cambray, S; Suarez, I; Sanahuja, J; Farre, J; Benabdelhak, I

    Metabolomics discriminate etiologic subtypes among TIA patients

    INTERNATIONAL JOURNAL OF STROKE 10 222-222. .

  • Jové M; Mauri-Capdevila G; Suárez I; Cambray S; Sanahuja J; Quílez A; Farré J; Benabdelhak I; Pamplona R; Portero-Otín M; Purroy F

    Metabolomics predicts stroke recurrence after transient ischemic attack

    Neurology 84 36-45. .

    [doi:10.1212/WNL.0000000000001093]

  • Ansoleaga B; Jové M; Schlüter A; Garcia-Esparcia P; Moreno J; Pujol A; Pamplona R; Portero-Otín M; Ferrer I

    Deregulation of purine metabolism in Alzheimer's disease

    NEUROBIOLOGY OF AGING 36 68-80. .

    [doi:10.1016/j.neurobiolaging.2014.08.004]

  • Jové M; Naudí A; Portero-Otin M; Cabré R; Rovira-Llopis S; Bañuls C; Rocha M; Hernández-Mijares A; Victor VM; Pamplona R

    Plasma lipidomics discloses metabolic syndrome with a specific HDL phenotype

    FASEB JOURNAL 28 5163-5171. .

    [doi:10.1096/fj.14-253187]

  • Cacabelos, D.; Ayala, V.; Ramírez-Nunez, O.; Granado-Serrano, A.B.; Boada, J.; Serrano, J.C.E.; Cabré, R.; Nadal-Rey, G.; Bellmunt, M.J.; Ferrer, I.; Pamplona, R.; Portero-Otin, M.

    Dietary Lipid Unsaturation Influences Survival and Oxidative Modifications of an Amyotrophic Lateral Sclerosis Model in a Gender-Specific Manner

    NEUROMOLECULAR MEDICINE 16 669-685. .

    [doi:10.1007/s12017-014-8317-7]

  • Blasco G; Puig J; Daunis-I-Estadella J; Molina X; Xifra G; Fernández-Aranda F; Pedraza S; Ricart W; Portero-Otín M; Fernández-Real JM

    Brain Iron Overload, Insulin Resistance, and Cognitive Performance in Obese Subjects: A Preliminary MRI Case-Control Study

    Diabetes Care 37 3076-3083. .

    [doi:10.2337/dc14-0664]

  • Jové, M.; Naudí, A.; Ramírez-Núñez, O.; Portero-Otín, M.; Selman, C.; Withers, D.J.; Pamplona, R.

    Caloric restriction reveals a metabolomic and lipidomic signature in liver of male mice

    AGING CELL 13 828-837. .

    [doi:10.1111/acel.12241]

  • Gou-Fabregas M; Ramírez-Núñez O; Cacabelos D; Bahi N; Portero M; Garcera A; Soler RM

    Calpain activation and CaMKIV reduction in spinal cords from hSOD1G93A mouse model

    MOLECULAR AND CELLULAR NEUROSCIENCE 61 219-225. .

    [doi:10.1016/j.mcn.2014.07.002]

  • Stack C; Jainuddin S; Elipenahli C; Gerges M; Starkova N; Starkov AA; Jové M; Portero-Otin M; Launay N; Pujol A; Kaidery NA; Thomas B; Tampellini D; Beal MF; Dumont M

    Methylene blue upregulates Nrf2/ARE genes and prevents tau-related neurotoxicity

    HUMAN MOLECULAR GENETICS 23 3716-3732. .

    [doi:10.1093/hmg/ddu080]

  • Granados-Principal, S.; El-azem, N.; Pamplona, R.; Ramirez-Tortosa, C.; Pulido-Moran, M.; Vera-Ramirez, L.; Quiles, J.L.; Sanchez-Rovira, P.; Naudí, A.; Portero-Otin, M.; Perez-Lopez, P.; Ramirez-Tortosa, M.

    Hydroxytyrosol ameliorates oxidative stress and mitochondrial dysfunction in doxorubicin-induced cardiotoxicity in rats with breast cancer

    BIOCHEMICAL PHARMACOLOGY 90 25-33. .

    [doi:10.1016/j.bcp.2014.04.001]

  • Jové M; Portero-Otín M; Naudí A; Ferrer I; Pamplona R

    Metabolomics of Human Brain Aging and Age-Related Neurodegenerative Diseases

    JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY 73 640-657. .

    [doi:10.1097/NEN.0000000000000091]

  • Serviá, L.; Trujillano, J.; Serrano, J.C.E.; Pamplona, R.; Badia, M.; Jové, M.; Justes, M.; Domingo, J.; Portero-Otin, M.

    Plasma antioxidant capacity in critical polytraumatized patients ?: methods, severity, and anatomic location

    Critical Care 18 434-434. .

    [doi:10.1186/cc13917]

Projects

  • SEED-ALS: Synergizing Efforts to Develop and Accelerate Breakthroughs in ALS Research
  • Natural microbicides from rice against current and emerging infectious diseases
  • Humanised mouse models to study ATG4B cryptic exon involvement in ALS pathogenesis and its potential as disease biomarker (Hum4ALS)
  • Targeting cryptic exons as biomarkers and ALS therapy
  • Desregulacion de TDP-43,eje clave en la ELA: Caracterización de firmas lipidómicas, transcriptómicas y autofágicas en muestras específicas de pacientes para biomarcadores y reposicionamiento
  • Comprehensive Roadmap and Preclinical Evaluation of Antisense Oligonucleotides (ASOs) Regulatory Development and Toxicological Assessment for ALS Treatment
  • The role of defects in mitochondria-associated ER membranes (MAM) to Amyotrophic Lateral Sclerosis
  • Perspectivas clínicas de la biología de sistemas aplicada al análisis de placas carotídeas humanas: ILER-CAROTID
  • Metabolismo lipidico intracelular, procesamiento de ARNm y estrés celular en la encrucijada de la fisiopatología de la esclerosis lateral amiotrófica
  • Identification of compounds for inhibition of ACE2 membrane expression
  • Reposicionamiento terapéutico dirigido a inhibición de expresión de ACE2 y de proteolisis de trímero S viral
  • Determinació de components bioactius derivats de la microbiota mitjançant micromostreig